LY2452473
Based on 7 publication(s) in Google Scholar
LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.47%
- No. CAS: 1029692-15-6
- Fòrmula: C22H22N4O2
- Peso molecular:374.44
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-112256
ACP-105Androgen Receptor Modulator -
HY-14383
VosilasarmAndrogen Receptor Modulator -
HY-13273
OstarineSARMs -
HY-100186
GSK-2881078Androgen Receptor Modulator -
HY-12023
GTx-007Androgen Receptor SARM -
HY-15194
DimethylcurcuminAndrogen Receptor Inhibitor -
HY-13981
LigandrolAndrogen Receptor Agonist -
HY-11027
MK-0773Androgen Receptor Inhibitor -
HY-122025
AC-262536Androgen Receptor Agonist -
HY-107480
YK11Androgen Receptor Partial Agonist -
HY-138641
BavdegalutamideAR PROTAC Degrader -
HY-112257
S-23Selective Androgen Receptor Modulator
Publications Citing Use of MedChemExpress (MCE) LY2452473
More- ACS Omega. 2022 Aug 29;7(36):31845-31868. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113849. [Abstract]
- Drug Test Anal. 2021 May;13(5):916-928. [Abstract]
- Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2026 Feb 26:1-17. [Abstract]
- Rapid Commun Mass Spectrom. 2023 Jul 30;37(14):e9530. [Abstract]
- Rapid Commun Mass Spectrom. 2023 May 15;37(9):e9491. [Abstract]
- Biomed Pharmacother. 2024 Nov:180:117523. [Abstract]
Actividad biológica
Descripciòn
IC50 & Target
Androgen receptor[1]
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1029692-15-6
-
Appearance Solid
-
Peso molecular 374.44
-
Fòrmula C22H22N4O2
-
Color White to off-white
-
SMILES
O=C(N[C@@H]1CC(N(C2=C3C=C(C=C2)C#N)CC4=NC=CC=C4)=C3C1)OC(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
ACS Omega
UHPLC-HRMS Method for the Simultaneous Screening of 235 Drugs in Capillary Blood for Doping Control Purpose: Comparative Evaluation of Volumetric and Non-volumetric Dried Blood Spotting Devices. [Abstract]2022 Aug 29;7(36):31845-31868. PMID: 36119994 -
J Pharm Biomed Anal
Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques. [Abstract]2021 Feb 20:195:113849. PMID: 33383501 -
Drug Test Anal
An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. [Abstract]2021 May;13(5):916-928. PMID: 33283964 -
Food Addit Contam Part A Chem Anal Control Expo Risk Assess
Comprehensive IM-MS approach for SARMs detection in urine: building CCS databases to support food safety monitoring. [Abstract]2026 Feb 26:1-17. PMID: 41747154 -
Rapid Commun Mass Spectrom
Electrospray ionisation mass spectrometry (ESI-MS) adduct formation by mobile phase additives: A case study using nitrile functional groups containing selective androgen receptor modulators (SARMs). [Abstract]2023 Jul 30;37(14):e9530. PMID: 37125537 -
Rapid Commun Mass Spectrom
Metabolic study of selective androgen receptor modulator LY2452473 in thoroughbred horses for doping control. [Abstract]2023 May 15;37(9):e9491. PMID: 36758220 -
Biomed Pharmacother
Polypharmacological profiling across protein target families and cellular pathways using the multiplexed cell-based assay platform safetyProfiler reveals efficacy, potency and side effects of drugs. [Abstract]2024 Nov:180:117523. PMID: 39405910
Solvente y solubilidad
In Vitro:
DMSO : 62.5 mg/mL (166.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6707 mL | 13.3533 mL | 26.7065 mL | 66.7664 mL |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3413 mL | 13.3533 mL | |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6707 mL | 6.6766 mL | |
| 15 mM | 0.1780 mL | 0.8902 mL | 1.7804 mL | 4.4511 mL | |
| 20 mM | 0.1335 mL | 0.6677 mL | 1.3353 mL | 3.3383 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0683 mL | 2.6707 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8902 mL | 2.2255 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6677 mL | 1.6692 mL | |
| 50 mM | 0.0534 mL | 0.2671 mL | 0.5341 mL | 1.3353 mL | |
| 60 mM | 0.0445 mL | 0.2226 mL | 0.4451 mL | 1.1128 mL | |
| 80 mM | 0.0334 mL | 0.1669 mL | 0.3338 mL | 0.8346 mL | |
| 100 mM | 0.0267 mL | 0.1335 mL | 0.2671 mL | 0.6677 mL |
LY2452473 Related Classifications
HY-114530 Related Classifications
Powered by Bioz